Overview

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Status:
Enrolling by invitation

Trial end date:
2023-10-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, open, dose escalation, single and multiple administration phase Ⅰ/Ⅱ clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and primary clinical efficacy of LY01616 in patients with advanced solid tumors

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Luye Pharma Group Ltd.

Treatments:

Floxuridine
Irinotecan